Stanley Tyler Hollmig Net Worth

The estimated Net Worth of Stanley Tyler Hollmig is at least $157 mil dollars as of 18 November 2022. Stanley Hollmig owns over 250,000 units of Venus Concept stock worth over $156,571 and over the last 3 years Stanley sold VERO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stanley Hollmig VERO stock SEC Form 4 insiders trading

Stanley has made over 2 trades of the Venus Concept stock since 2022, according to the Form 4 filled with the SEC. Most recently Stanley bought 250,000 units of VERO stock worth $50,000 on 18 November 2022.

The largest trade Stanley's ever made was buying 250,000 units of Venus Concept stock on 18 November 2022 worth over $50,000. On average, Stanley trades about 72,500 units every 45 days since 2022. As of 18 November 2022 Stanley still owns at least 290,000 units of Venus Concept stock.

You can see the complete history of Stanley Hollmig stock trades at the bottom of the page.

What's Stanley Hollmig's mailing address?

Stanley's mailing address filed with the SEC is 235 YORKLAND BLVD, SUITE 900, TORONTO, Z4, M2J 4Y8.

Insiders trading at Venus Concept

Over the last 5 years, insiders at Venus Concept have traded over $1,569,538 worth of Venus Concept stock and bought 13,477,963 units worth $14,979,486 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Gilbert H Kliman, eRichard Scott Barry. On average, Venus Concept executives and independent directors trade stock every 46 days with the average trade being worth of $222,494. The most recent stock trade was executed by Michael Willingham Masters ... on 7 June 2024, trading 489,948 units of VERO stock currently worth $587,938.

What does Venus Concept do?

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.

Complete history of Stanley Hollmig stock trades at Venus Concept

Venus Concept executives and stock owners

Venus Concept executives and other stock owners filed with the SEC include:

• Domenic Serafino,
  CEO & Director
• Chad A. Zaring,
  Consultant
• Domenic Serafino,
  Chief Executive Officer, Director
• Domenic Della Penna,
  Chief Financial Officer
• Soren Maor Sinay,
  Chief Operating Officer
• Domenic Penna,
  Chief Financial Officer
• Keith Sullivan,
  Director
• Fritz LaPorte,
  Independent Director
• Louise Lacchin,
  Independent Director
• Anthony Natale,
  Independent Director
• Garheng Kong,
  Independent Director
• Scott Barry,
  Independent Director
• Mike Piccinino,
  IR Contact Officer
• Chad Zaring,
  Chief Commercial Officer
• Yoni Iger,
  Vice President - Clinical and Regulatory Affairs
• Anna Georgiadis,
  Vice President of Global Human Resources
• Melissa Kang,
  Vice President of Marketing
• Soren Sinay,
  Chief Operating Officer
• Kenji Shimizu,
  Interim Chief Innovation Officer
• Anat Kotler,
  VP of Global Marketing & Product Management
• Dr. Hemanth Jacob Varghese CFA, Ph.D.,
  Pres & Chief Bus. Officer
• Rajiv Kanishka Liyanaarchchie De Silva,
  CEO & Director
• Anna Georgiadis,
  VP of Global HR
• Ross J. Portaro,
  Pres of Global Sales
• Melissa Kang,
  Exec. VP of Global Marketing & Product Management
• Michael Mandarello,
  Gen. Counsel & Corp. Sec.
• Soeren Maor Sinay,
  Chief Operating Officer
• Anat Kotler,
  Interim VP, Global Marketing
• Stanley Tyler Hollmig,
  Director
• Healthcare Partners, L.P.Ew...,
  
• Sisto Domenic Di,
  General Counsel and Corp. Sec.
• Frederic H Moll,
  Director
• Gilbert H Kliman,
  Director
• Boris Vaynberg,
  Chief Technology Officer
• William Bernard Kelley,
  President, Global Sales
• Capital Cayman Ltd Saudi Ec...,
  
• Partners Ii, L.P.Health Que...,
  
• Partners Ix, Lp Inter West ...,
  
• Bakker Juliet Tammenoms,
  Director
• Ross Portaro,
  Exec VP & General Manager
• Michael Mandarello,
  General Counsel & Secretary
• William H Mcgrail,
  Sr. VP
• Hemanth Jacob Varghese,
  President/Chief Bus. Officer
• Kenji Shimizu,
  Interim CTO
• Silva Rajiv De,
  Officer
• Michael Willingham Masters ...,